Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 548280, 12 pages
Review Article

A New Insight into Hepatitis C Vaccine Development

Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, No. 1 Chang-Te Street, Taipei 100, Taiwan

Received 14 December 2009; Revised 25 February 2010; Accepted 5 April 2010

Academic Editor: Zhengguo Xiao

Copyright © 2010 Chun I. Yu and Bor-Luen Chiang. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Chronic hepatitis C virus (HCV) infection remains a serious burden to public health worldwide. Currently, HCV-infected patients could undergo antiviral therapy by giving pegylated IFN- 𝛼 with ribavirin. However, this therapy is only effective in around 50% of patients with HCV genotype 1, which accounts for more than 70% of all HCV infection, and it is not well tolerated for most patients. Moreover, there is no vaccine available. The efforts on identifying protective immunity against HCV have progressed recently. Neutralizing antibodies and robust T cell responses including both C D 4 + and C D 8 + have been shown to be related to the clearance of HCV, which have shed lights on the potential success of HCV vaccines. There are many vaccines developed and tested before entering clinical trials. Here, we would first discuss strategies of viral immune evasion and correlates of protective host immunity and finally review some prospective vaccine approaches against chronic HCV infection.